Yanira Ruiz-Heredia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7130959/publications.pdf

Version: 2024-02-01

1684188 1872680 10 86 5 6 citations g-index h-index papers 10 10 10 236 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia. Haematologica, 2019, 104, 288-296.	3.5	36
2	Concurrent progressive multifocal leukoencephalopathy and central nervous system infiltration by multiple myeloma: A case report. Journal of Oncology Pharmacy Practice, 2019, 25, 998-1002.	0.9	14
3	Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing. Haematologica, 2018, 103, e544-e548.	3.5	13
4	Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with <i>ex vivo</i> chemosensitivity. British Journal of Haematology, 2020, 189, 672-683.	2.5	11
5	A novel targeted RNA-Seq panel identifies a subset of adult patients with acute lymphoblastic leukemia with BCR-ABL1-like characteristics. Blood Cancer Journal, 2020, 10, 43.	6.2	10
6	Prognostic Impact of Molecular Response Assessed By Next-Generation Sequencing in a Large Cohort of Multiple Myeloma Patients. Blood, 2016, 128, 3283-3283.	1.4	2
7	Ultra-Deep Targeted Sequencing Does Not Identify MM Patients with Different Prognosis: Results from a Randomized Phase II Clinical Trial. Blood, 2016, 128, 2078-2078.	1.4	O
8	Focusing PI and IMiD Resistance in Multiple Myeloma: Impact of DNA Methylation. Blood, 2018, 132, 404-404.	1.4	0
9	Increase of Mitochondrial Activity Contributes to the Bortezomib-Relapsed in Multiple Myeloma, a Novel Therapeutic Opportunity. Blood, 2019, 134, 4408-4408.	1.4	O
10	Making Clinical Decisions to Change Therapy Using Measurable Residual Disease Improves the Outcome in Multiple Myeloma. Blood, 2020, 136, 42-43.	1.4	0